Kindeva Drug Delivery’s global health security division, Meridian Medical Technologies, secured a contract valued at up to $129 million to supply DuoDote, a chemical nerve agent antidote autoinjector, to the Strategic National Stockpile (SNS), managed by the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services.
Thx4Stock team Shutterstock
DuoDote is an FDA-approved dual-chamber autoinjector, containing atropine and pralidoxime chloride, and is indicated for the treatment of poisoning by organophosphorus nerve agents as well as organophosphorus insecticides.
Kindeva manufactures DuoDote in the U.S. for distribution at strategic locations across the U.S. as part of the country’s emergency preparedness program to protect civilians from chemical nerve agent attacks. The treatment will be stockpiled and available for rapid deployment as part of the SNS CHEMPACK program.
Milton Boyer, CEO of Kindeva, said: “Kindeva is a global force in medical countermeasure development, manufacturing and supply. As a trusted partner to the SNS, this contract underscores the ongoing importance of maintaining readiness against potential threats.”
Boyer continued: “Our long-standing partnership with the SNS reflects our commitment to national preparedness and our ability to deliver crucial medical countermeasures when they are needed most. With our extensive experience in this space, we are proud to continue supporting the U.S. government’s efforts to protect public health and safety.”
The DuoDote autoinjectors will be manufactured and distributed from Kindeva’s fill-finish facility in St. Louis, Missouri. Kindeva is a leading global CDMO with vast expertise in drug delivery devices.